Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing
25/08/2026 21:12
BRIEF-Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing Aug 25 (Reuters) - PDS Biotechnology Corp PDSB.O:
PDS BIOTECHNOLOGY CORP - ON AUG 6, APPROVED REDUCTION IN FORCE TO ALIGN EXPENSES WITH STRATEGIC PRIORITIES - SEC FILING
PDS BIOTECHNOLOGY CORP - REDUCTION IN FORCE TO AFFECT ABOUT 36% OF WORKFORCE, COMPLETION EXPECTED IN Q3 2026 - SEC FILING
PDS BIOTECHNOLOGY CORP - STEPHAN TOUTAIN REMOVED AS CHIEF OPERATING OFFICER EFFECTIVE AUGUST 21, 2026 - SEC FILING
Source text: []
Further company coverage: PDSB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing